ArticleCancer management and research2026
Parameters That May Predict NAC Effectiveness in Hormone-Positive Breast Cancer According to CPS Score.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neoadjuvant chemotherapy (NAC) in hormone-positive operable breast cancer supports breast-conserving surgery, axillary dissection, and survival. However, the pathological complete response (pCR) rates to NAC in hormone-positive breast cancer remain low. Identifying the predictive parameters for pathological response prior to NAC is crucial. In this study, we investigated clinical, pathological, inflammatory, and metabolic parameters that could predict NAC response and survival. Material and Methods: A retrospective study was conducted on 120 patients with hormone-positive breast cancer. Clinical and pathological stages of patients who underwent surgery following NAC were used to calculate the CPS score (clinical stage score + pathological stage score). The Kruskal Wallis test was employed to compare clinical, pathological, and laboratory parameters with the CPS score. The Bonferroni test was applied for post-hoc analysis. Categorical variables were compared using the Pearson Chi-Square test or Fisher's exact test. Results: There was no statistically significant association between the CPS score and age (p=0.106), estrogen receptor positivity (p=0.331), grade (p=0.100), Ki67 (p=0.247), and chemotherapy received (p=0.720). While pCR was statistically significant in univariate analysis (p=0.001), it did not reach statistical significance in the multivariate model (p=0.258). Axillary pathological response (ypN) had a statistically significant correlation with the CPS score (p=0.003). There was no statistically significant association between the CPS score and leukocyte, lymphocyte, neutrophil, or platelet counts, glucose levels, NLR, PNI, or SII values (p > 0.05). Conclusion: ypN was associated with the CPS score in predicting survival following NAC in hormone-positive breast cancer. No statistically significant association was observed between inflammatory or metabolic parameters and the CPS score. Further validation in larger studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.